Research programme: CovX-Bodies - Pfizer
Alternative Names: CVX 37; CVX-22; CVX-63Latest Information Update: 04 Nov 2017
At a glance
- Originator CovX
- Class Antibodies; Recombinant fusion proteins
- Mechanism of Action Angiogenesis inhibitors; Angiopoietin-2 inhibitors; Glucagon-like peptide-1 receptor agonists; HIV fusion inhibitors; Thrombospondin 1 agonists; Vascular endothelial growth factor A inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer; Diabetes mellitus
- Discontinued HIV infections
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Diabetes-mellitus in USA (Parenteral, Injection)
- 28 Oct 2009 This programme is still in active development